453 related articles for article (PubMed ID: 28979113)
1. Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function.
Lim JU; Kim K; Kim SH; Lee MG; Lee SY; Yoo KH; Lee SH; Jung KS; Rhee CK; Hwang YI
Int J Chron Obstruct Pulmon Dis; 2017; 12():2711-2721. PubMed ID: 28979113
[TBL] [Abstract][Full Text] [Related]
2. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010.
Tsai YH; Yang TM; Lin CM; Huang SY; Wen YW
Int J Chron Obstruct Pulmon Dis; 2017; 12():2787-2793. PubMed ID: 29026296
[TBL] [Abstract][Full Text] [Related]
3. Natural course of early COPD.
Rhee CK; Kim K; Yoon HK; Kim JA; Kim SH; Lee SH; Park YB; Jung KS; Yoo KH; Hwang YI
Int J Chron Obstruct Pulmon Dis; 2017; 12():663-668. PubMed ID: 28255237
[TBL] [Abstract][Full Text] [Related]
4. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
Punekar YS; Landis SH; Wurst K; Le H
Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
[TBL] [Abstract][Full Text] [Related]
5. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
6. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea.
Kim C; Yoo KH; Rhee CK; Yoon HK; Kim YS; Lee SW; Oh YM; Lee SD; Lee JH; Kim KJ; Kim JH; Park YB
Int J Tuberc Lung Dis; 2014 Jun; 18(6):737-43. PubMed ID: 24903947
[TBL] [Abstract][Full Text] [Related]
7. Identification of subtypes in subjects with mild-to-moderate airflow limitation and its clinical and socioeconomic implications.
Lee JH; Rhee CK; Kim K; Kim JA; Kim SH; Yoo KH; Kim WJ; Park YB; Park HY; Jung KS
Int J Chron Obstruct Pulmon Dis; 2017; 12():1135-1144. PubMed ID: 28442900
[TBL] [Abstract][Full Text] [Related]
8. Trend of cost and utilization of COPD medication in Korea.
Lee J; Lee JH; Kim JA; Rhee CK
Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
[TBL] [Abstract][Full Text] [Related]
9. Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.
Lee JK; Rhee CK; Kim K; Ra SW; Lee JH; Jung KS; Yoo KH; Kim YI; Kim DK
Int J Chron Obstruct Pulmon Dis; 2019; 14():2639-2647. PubMed ID: 31819397
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
Bengtson LGS; DePietro M; McPheeters J; Fox KM
Ther Adv Respir Dis; 2018; 12():1753466618772750. PubMed ID: 29737943
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
[TBL] [Abstract][Full Text] [Related]
12. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
[TBL] [Abstract][Full Text] [Related]
13. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
15. Factors contributing to high-cost hospital care for patients with COPD.
Mulpuru S; McKay J; Ronksley PE; Thavorn K; Kobewka DM; Forster AJ
Int J Chron Obstruct Pulmon Dis; 2017; 12():989-995. PubMed ID: 28392683
[TBL] [Abstract][Full Text] [Related]
16. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
Schwab P; Dhamane AD; Hopson SD; Moretz C; Annavarapu S; Burslem K; Renda A; Kaila S
Int J Chron Obstruct Pulmon Dis; 2017; 12():735-744. PubMed ID: 28260880
[TBL] [Abstract][Full Text] [Related]
17. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
18. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
Ramadan WH; Kabbara WK; El Khoury GM; Al Assir SA
Int J Chron Obstruct Pulmon Dis; 2015; 10():2347-56. PubMed ID: 26586940
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of asthma and COPD overlap.
Kim MH; Rhee CK; Kim K; Kim SH; Lee JY; Kim YH; Yoo KH; Cho YJ; Jung KS; Lee JH
Int J Chron Obstruct Pulmon Dis; 2018; 13():1251-1260. PubMed ID: 29713158
[TBL] [Abstract][Full Text] [Related]
20. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
